In the heightened microglial activation response, an exaggerated mROS/c-Abl/NLRP3 signaling axis was confirmed [109], which suggested that targeting the c-Abl-regulated NLRP3 inflammasome signaling offers a therapeutic strategy for PD. Here, ABL1 is linked to Parkinson disease.